Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

NCT06597721 is registered in ClinicalTrials.gov with Adcendo ApS as lead sponsor.

NCT NCT06597721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06597721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Lead sponsor
Adcendo ApS
Phase
Phase 1
Overall status
Recruiting
Start date
November 25, 2024
Completion date
June 30, 2027
Enrollment
210 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, hnscc, pdac